Product Name: IGF1R-BKCD
Product Number: AB-NK074-2
| Size: | 25 µg | Price: | 89.00 | |
| $US |
Target Full Name: Insulin-like growth factor 1 receptor protein-tyrosine kinase
Target Alias: CD221; IGFIR; Insulin-like growth factor I receptor; JTK13; MGC142170; MGC142172
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK074-2
Antibody Target Type: Pan-specific
Protein UniProt: P08069
Protein SigNET: P08069
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human IGF1R sequence peptide Cat. No.: PE-01BDE99
Antibody Immunogen Sequence: VIMLYVFHRKRNNSRLGC
Target Alias: CD221; IGFIR; Insulin-like growth factor I receptor; JTK13; MGC142170; MGC142172
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK074-2
Antibody Target Type: Pan-specific
Protein UniProt: P08069
Protein SigNET: P08069
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human IGF1R sequence peptide Cat. No.: PE-01BDE99
Antibody Immunogen Sequence: VIMLYVFHRKRNNSRLGC
Antibody Immunogen Description: Corresponds to amino acid residues V952 to G968; Just before kinase catalytic domain
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.5 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 90-100, 130 kDa.
Related Product 1: IGF1R-BKCD blocking peptide
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 90-100, 130 kDa.
Related Product 1: IGF1R-BKCD blocking peptide
Related Product 2: IGF1R-CT pan-specific antibody (Cat. No.: AB-NK074-3)
Related Product 3: IGF1R-pY1161+pT1163 phosphosite-specific antibody (Cat. No.: AB-PK657)
Related Product 4: IGF1R-pY1346 phosphosite-specific antibody (Cat. No.: AB-PK658)
Related Product 3: IGF1R-pY1161+pT1163 phosphosite-specific antibody (Cat. No.: AB-PK657)
Related Product 4: IGF1R-pY1346 phosphosite-specific antibody (Cat. No.: AB-PK658)
Scientific Background: IGF1R is a protein-tyrosine kinase of the TK group and InsR family. It mediates the effects of its ligand insulin-like growth factor 1 (IGF1) to promote cell growth and survival. The pre-dimerized receptor also displays weak affinity for both insulin and IGF2. Once ligand bound, the IGF1R undergoes autophosphorylation and activates several downstream signalling pathways, including the PI3K-Akt pathway and the Ras/Raf/MAP kinase pathway to induce cell growth and survival. Autophosphorylation Y1161 and Y346 increases its phosphotransferase activity and induces interaction with Src. Y1346 autophosphorylation also mediates GRB10 binding to IGF1R. Y980, Y1161, Y1165 and Y1166 autophosphorylation also increases its phosphotransferase activity. Y980 autophosphorylation also appears to mediate IRS1 or Shc1 interactions with IGF1R. IGFR1 is an oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. IGF1R been shown to be an important signalling component in several types of human cancers. In particular, the activated receptor is critical for tumour transformation, malignant cell survival, and the maintenance of the transformed phenotype. In addition, activated IGF1R protein functions to inhibit apoptosis via indirect phosphorylation of the BAD protein via Akt, as well as plays an important role in the regulation of cancer cell motility and metastasis. Several cancer types display increased expression of IGF1R and/or increased catalytic activity of the protein, including prostate cancer, colorectal adenoma, and melanoma. Additionally, cross-talk between the IGF signalling pathway and the estrogen receptor signalling pathway has been demonstrated in breast cancer cells as a central mechanism of cell growth regulation. Furthermore, therapies aimed at the inhibition of IGF1R signalling have shown promise as potential cancer treatments. Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.
© Kinexus Bioinformatics Corporation 2017